ASGCT 2022 -- CAR T cells must not persist or expand beyond their therapeutic window. Preclinical animal studies of CAR T cell persistence are expensive, lengthy and may not detect persistent CAR T cells across matrices. We have developed a cell viability and proliferation assay to track CAR T cell persistence in vitro.

Welcome to the May 2022 Labcorp Drug Development Decentralized Clinical Trial (DCT) blog. Because spring is a time traditionally packed with industry conferences, we will devote this blog to reviewing some of the highlights of our plans for the spring conference season.

At Labcorp, we strive to be more than just a partner. The snapClinical� platform supports wearable sensors such as glucose meters or actimetry devices for continuous biometric data collection.

A large pharmaceutical company was running a complex antibiotic study for a treatment targeting complicated intra-abdominal infection (cIAI). Based on extensive experience with facilitating and executing these complex antibiotic studies, Labcorp Drug Development was selected to support this Phase IIb trial.

We serve as an extension of your team, working seamlessly to bring together the right expertise, technology, data and processes for your dermatology study. We're more than a global contract research organization -- we know how to anticipate your needs and create value for your medical and cosmetic program.

A small biotech company worked with Labcorp Drug Development starting with clinical pharmacology and Phase Ia/IIb studies to determine the best path forward for their molecules targeting Type 1 diabetes.

Obtaining approval from several regulatory agencies around the world requires a coordinated effort and a strategic partnership.

A large pharmaceutical company chose Labcorp Drug Development to support its ongoing Phase II study evaluating patients with cUTI.

A small biopharmaceutical company, developing a novel therapeutic platform, engaged Labcorp Drug Development to set up and conduct a global, Phase III, pivotal clinical trial on a promising treatment for a rare genetic cardiovascular disease.

A small-to mid-size pharmaceutical company in India was developing a new combination treatement for complicated urinary tract infection. They were starting studies in the U.S. and EU but also wanted to evaluate their treatment in China with a Phase III trial.